Bias assessment of studies that evaluated persistence with methotrexate in patients with RA.
| Study | Representativeness of the Sample | Clinical Confirmation of RA | Appropriate Accounting for Loss to Followup | Completeness and Accuracy of Data | Appropriate Accounting for Confounders |
|---|---|---|---|---|---|
| Prospective studies | |||||
| Alarcón, et al 28,29 | − | + | + | +/− | +/− |
| Wolfe, et al30 | − | ? | + | +/− | +/− |
| Salaffi, et al34 | +/− | + | + | +/− | NA |
| De La Mata, et al35 | +/− | + | +/− | +/− | NA |
| Papadopoulos, et al41 | +/− | + | ? | +/− | NA |
| Wolfe, et al43 | − | ? | − | +/− | NA |
| Lie, et al47 | + | − | + | +/− | NA |
| Lie, et al48 | + | + | + | +/− | NA |
| Gibofsky, et al53 | ? | + | − | − | − |
| Retrospective studies | |||||
| Scully, et al31 | +/− | + | + | +/− | NA |
| Tishler, et al32 | +/− | + | + | +/− | ? |
| McKendry and Dale33 | +/− | + | + | +/− | NA |
| Buchbinder, et al37 | +/− | + | + | +/− | − |
| Keysser, et al36 | − | ? | +/− | +/− | NA |
| Wluka, et al38 | +/− | + | +/− | +/− | − |
| Ortendahl, et al39 | +/− | + | + | +/− | +/− |
| Aletaha and Smolen40 | +/− | + | + | +/− | − |
| Hoekstra, et al42 | + | ? | + | +/− | + |
| Yazici, et al44 | − | + | + | +/− | NA |
| Kapral, et al49 | − | + | − | +/− | NA |
| Ideguchi, et al45 | +/− | + | − | +/− | + |
| Bernatsky and Ehrmann Feldman50 | + | − | − | +/− | + |
| Agarwal, et al46 | ? | + | − | − | ? |
| Scott, et al51 | ? | ? | − | − | NA |
| Curtis, et al52 | + | ? | ? | ? | NA |
| Nikiphorou, et al54 | ? | ? | ? | ? | NA |
| Bliddal, et al55 | + | − | ? | +/− | +/− |
| Branco, et al56 | − | + | ? | + | NA |
RA: rheumatoid arthritis; +/−: adequate; ?: unclear; NA: not applicable.